A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

F Lakha; P C Ho; Z M Van der Spuy; K Dada; R Elton; A F Glasier; H O D Critchley; A R W Williams; D T Baird

doi:10.1093/humrep/dem177

A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

F Lakha, P C Ho, Z M Van der Spuy, K Dada, R Elton, A F Glasier, H O D Critchley, A R W Williams, D T Baird

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives.

Original language	English
Pages (from-to)	2428-36
Number of pages	9
Journal	Human Reproduction
Volume	22
Issue number	9
DOIs	https://doi.org/10.1093/humrep/dem177
Publication status	Published - 2007

Access to Document

10.1093/humrep/dem177

Development of new methods of contraception for men and women.
Critchley, H.
MRC
1/08/00 → 31/07/05
Project: Research

Cite this

Lakha, F., Ho, P. C., Van der Spuy, Z. M., Dada, K., Elton, R., Glasier, A. F., Critchley, H. O. D., Williams, A. R. W., & Baird, D. T. (2007). A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Human Reproduction, 22(9), 2428-36. https://doi.org/10.1093/humrep/dem177

@article{14a0aaff73294d43bf4ec055b29d6eca,

title = "A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)",

abstract = "The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives.",

author = "F Lakha and Ho, {P C} and {Van der Spuy}, {Z M} and K Dada and R Elton and Glasier, {A F} and Critchley, {H O D} and Williams, {A R W} and Baird, {D T}",

year = "2007",

doi = "10.1093/humrep/dem177",

language = "English",

volume = "22",

pages = "2428--36",

journal = "Human Reproduction",

issn = "0268-1161",

publisher = "Oxford University Press",

number = "9",

}

Lakha, F, Ho, PC, Van der Spuy, ZM, Dada, K, Elton, R, Glasier, AF, Critchley, HOD, Williams, ARW & Baird, DT 2007, 'A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)', Human Reproduction, vol. 22, no. 9, pp. 2428-36. https://doi.org/10.1093/humrep/dem177

TY - JOUR

T1 - A novel estrogen-free oral contraceptive pill for women

T2 - multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

AU - Lakha, F

AU - Ho, P C

AU - Van der Spuy, Z M

AU - Dada, K

AU - Elton, R

AU - Glasier, A F

AU - Critchley, H O D

AU - Williams, A R W

AU - Baird, D T

PY - 2007

Y1 - 2007

N2 - The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives.

AB - The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable bleeding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity of the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel contraceptives.

U2 - 10.1093/humrep/dem177

DO - 10.1093/humrep/dem177

M3 - Article

C2 - 17609247

SN - 0268-1161

VL - 22

SP - 2428

EP - 2436

JO - Human Reproduction

JF - Human Reproduction

IS - 9

ER -

A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

Abstract / Description of output

Access to Document

Fingerprint

Projects

Development of new methods of contraception for men and women.

Cite this